For the Inventor, By the Inventor

Enter assignee name

Carlsbad, CA, United States of America

Isis Pharmaceuticals, Inc.

USPTO Granted Patents = 1,035

CIPO Patents = 6

EPO Patents = 68

Trademarks = 4

Forward Citations = 46,652

Loading Chart...

Loading Chart...

395 inventors (with patents filed for the assignee):

Phillip Dan Cook (176 out of 185 patents)

Lex M Cowsert (144 out of 146 patents)

C Frank Bennett (134 out of 202 patents)

4. Brett P Monia (131 out of 147 patents)

5. Muthiah Manoharan (125 out of 323 patents)

6. Eric E Swayze (109 out of 201 patents)

7. Susan M Freier (103 out of 254 patents)

8. Kenneth W Dobie (68 out of 76 patents)

9. Vasulinga T Ravikumar (65 out of 66 patents)

10. David J Ecker (60 out of 104 patents)

11. Jacqueline R Wyatt (53 out of 55 patents)

12. Punit P Seth (49 out of 110 patents)

13. Richard Holmes Griffey (49 out of 110 patents)

14. Sanjay Bhanot (48 out of 62 patents)

15. Nicholas M Dean (48 out of 54 patents)

Core Competencies:

Angiopoietin-Like 3

Tau Expression

Signal Transducer and Activator of Transcription 3

Tricyclic Nucleic Acid Analogs

Conjugated Antisense Compounds

Apolipoprotein C-III

Chimeric Oligomeric Compounds

Hepatitis B Virus Modulation

Oligomeric Compounds

Gene Modulation

Antisense Oligonucleotides

Cellular Uptake Improvement

1,035 patents: Sort by Forward Citations

1. 10875884 - Compositions and methods for modulating angiopoietin-like 3 expression (2020-12-29),

2. 10273474 - Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome (2019-04-30),

3. 9382540 - Compositions and methods for modulating angiopoietin-like 3 expression (2016-07-05),

4. 9359608 - Modulation of signal transducer and activator of transcription 3 (STAT3) expression (2016-06-07),

5. 9243291 - Methods of predicting toxicity (2016-01-26),

6. 9221864 - Tricyclic nucleic acid analogs (2015-12-29),

7. 9193752 - 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom (2015-11-24),

8. 9187749 - Methods for modulating factor 12 expression (2015-11-17),

9. 9181550 - Compositions and methods for modulating apolipoprotein (a) expression (2015-11-10),

10. 9181549 - Conjugated antisense compounds and their use (2015-11-10),

11. 9175291 - Modulation of androgen receptor expression (2015-11-03),

12. 9163239 - Compositions and methods for modulating apolipoprotein C-III expression (2015-10-20),

13. 9157082 - Modulation of apolipoprotein CIII (ApoCIII) expression (2015-10-13),

14. 9157081 - Chimeric oligomeric compounds for modulation of splicing (2015-10-13),

15. 9156873 - Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom (2015-10-13),

Isis Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on discovering and developing RNA-targeted drugs for the treatment of various diseases. With a deep understanding of RNA biology and antisense technology, Isis Pharmaceuticals has successfully developed innovative therapies to address unmet medical needs. Their research and development efforts are aimed at transforming the way diseases are treated, particularly in areas such as cardiovascular, metabolic, neurodegenerative, and severe and rare diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

1,035 Patents

#5 in Carlsbad, CA

#116 in California

#478 in US

#951 in the World

Carlsbad, CA, United States of America

Isis Pharmaceuticals, Inc.

Forward Citations = 46,652

395 inventors:

Phillip Dan Cook (176 out of 185 patents)

Lex M Cowsert (144 out of 146 patents)

C Frank Bennett (134 out of 202 patents)

4. Brett P Monia (131 out of 147 patents)

5. Muthiah Manoharan (125 out of 323 patents)

Please report any incorrect information to support@idiyas.com

Loading…